Clinical Edge Journal Scan

Study Identifies Risk Factors for Development of Psoriasis To Clinical PsA


 

Key clinical point: Risk factors for psoriasis developing into clinical psoriatic arthritis (PsA) include higher age, nail involvement, increased erythrocyte sedimentation rate (ESR), and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Major finding: Age ≥ 40 years (odds ratio [OR], 1.04; P < .01), nail involvement (OR, 1.17; P < .01), increased ESR (OR, 1.03; P < .05), and elevated hs-CRP levels (OR, 1.31; P < .01) increased the risk for incident PsA in patients with psoriasis. Moreover, MRI-detected enthesitis and tenosynovitis combined with these risk factors vs the risk factors alone showed better specificity (94.3% vs 69.0%) and similar sensitivity (89.0% vs 84.6%) in diagnosing PsA.

Study details: This longitudinal case-control study included 75 patients diagnosed with clinical PsA who were compared with 345 patients with psoriasis and without PsA, all of whom were aged 18-65 years.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Project. The authors declared no conflict of interests.

Source: Yao A, Wang L, Qi F, et al. Risk factors and early detection of joint damage in patients with psoriasis: A case–control study . Int J Dermatol. Published online April 29, 2024 . Source

Recommended Reading

Real World Study Confirms Efficacy of Risankizumab in PsA
MDedge Rheumatology
Meta-Analysis Identifies IL17A Inhibitor as a Better Treatment Option in Biologic-Naive Patients with PsA
MDedge Rheumatology
Clinical Characteristics of Severe PsA
MDedge Rheumatology
Second Ustekinumab Biosimilar Gets FDA Approval
MDedge Rheumatology
Combined Pediatric Derm-Rheum Clinics Supported by Survey Respondents
MDedge Rheumatology
Commentary: Comparisons Among PsA Therapies, May 2024
MDedge Rheumatology
Poor Use of ICD-10 Rheumatology Codes Suggests New Approach Needed for ICD-11 Adoption
MDedge Rheumatology
Secukinumab Safe and Effective in Challenging-to-Treat Patients With PsA
MDedge Rheumatology
Risankizumab Shows Long-Term Efficacy in PsA Regardless of Baseline Characteristics
MDedge Rheumatology
Elevated Risk for PsA in Patients With Psoriasis and Arthralgia
MDedge Rheumatology